Funds advised by Bain Capital Private Equity, LP (“Bain Capital”) and by Cinven Partners LLP (“Cinven”), announced the intention to launch a voluntary public takeover offer (the “Takeover Offer”) for all outstanding shares of STADA Arzneimittel AG (“STADA” or the “Company”).

STADA is a leading, independent pharmaceutical company listed on the Frankfurt Stock Exchange. The Company offers a comprehensive portfolio of high-quality, low-cost generic products including selected biosimilars. STADA has also built an attractive portfolio of well-established branded products, including the cold medicine Grippostad® and the Ladival® range of sun protection products.

APP conducted the commercial and product due diligence and advised on all industry aspects of the transaction.